Breaking News

Sanofi Expands Medidata Cloud Platform

April 29, 2014

Leverages RaveTSDV technology for risk-based monitoring of clinical trial sites

Sanofi has increased its adoption of the Medidata Clinical Cloud as part of a company-wide initiative aimed at increasing productivity across its global R&D organization. Sanofi will now leverage Miedidata’s technology for risk-based monitoring of clinical trial sites, in addition to the solutions and analytics currently used.
 
Sanofi is developing an industry-wide approach for targeted monitoring of clinical trial sites and has selected Medidata’s targeted source document verification, Medidata RaveTSDV, to provide a scalable and auditable technology solution for its clinical operations and data management teams.
 
“We’re proud that Medidata’s cloud-based platform is supporting Sanofi in driving the effective and high-quality delivery of new medicines to patients worldwide,” said Glen de Vries, president of Medidata. “Sanofi is an early adopter of risk-based monitoring practices and has been quick to implement TransCelerate’s recommendations on this important methodology, streamlining the way clinical trials are conducted and monitored around the world.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials